Braidwell LP Sells 102,864 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE)

Braidwell LP lowered its holdings in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 6.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,540,362 shares of the company's stock after selling 102,864 shares during the period. Apogee Therapeutics makes up about 2.1% of Braidwell LP's holdings, making the stock its 15th biggest position. Braidwell LP owned 3.42% of Apogee Therapeutics worth $69,778,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Mercer Global Advisors Inc. ADV acquired a new position in Apogee Therapeutics during the fourth quarter worth $32,621,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Apogee Therapeutics by 38.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,052,595 shares of the company's stock worth $47,683,000 after acquiring an additional 294,514 shares during the last quarter. Barclays PLC lifted its position in Apogee Therapeutics by 369.2% in the 3rd quarter. Barclays PLC now owns 365,046 shares of the company's stock valued at $21,443,000 after acquiring an additional 287,243 shares in the last quarter. Affinity Asset Advisors LLC boosted its stake in Apogee Therapeutics by 40.3% during the 4th quarter. Affinity Asset Advisors LLC now owns 931,728 shares of the company's stock valued at $42,207,000 after purchasing an additional 267,530 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. purchased a new stake in shares of Apogee Therapeutics in the fourth quarter worth approximately $10,881,000. 79.04% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Guggenheim reaffirmed a "buy" rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Citigroup started coverage on shares of Apogee Therapeutics in a report on Thursday, March 13th. They set a "buy" rating and a $95.00 price objective on the stock. Finally, Wedbush reiterated an "outperform" rating and issued a $90.00 target price on shares of Apogee Therapeutics in a report on Tuesday, March 11th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $92.17.

Insider Transactions at Apogee Therapeutics

In other Apogee Therapeutics news, insider Carl Dambkowski sold 1,590 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $30.48, for a total transaction of $48,463.20. Following the completion of the transaction, the insider now directly owns 251,033 shares of the company's stock, valued at approximately $7,651,485.84. This represents a 0.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael Thomas Henderson sold 10,000 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $30.15, for a total value of $301,500.00. Following the completion of the sale, the chief executive officer now owns 1,292,987 shares in the company, valued at approximately $38,983,558.05. The trade was a 0.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 18,175 shares of company stock worth $587,191 in the last quarter. Insiders own 36.10% of the company's stock.

Apogee Therapeutics Price Performance

Shares of Apogee Therapeutics stock traded down $0.52 during trading hours on Friday, hitting $37.29. 848,268 shares of the company's stock traded hands, compared to its average volume of 524,416. The stock has a market capitalization of $1.67 billion, a price-to-earnings ratio of -15.41 and a beta of 1.70. Apogee Therapeutics, Inc. has a 12-month low of $26.20 and a 12-month high of $63.50. The company has a fifty day simple moving average of $36.26 and a 200-day simple moving average of $41.65.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.25). On average, analysts forecast that Apogee Therapeutics, Inc. will post -3.09 EPS for the current fiscal year.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.